Abstract:ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) recently emerged as a severe worldwide public health concern. The virus is highly pathogenic, manifesting in infected patients with an approximately 50% fatality rate. It is known that the surface spike (S) proteins of coronaviruses mediate receptor recognition and membrane fusion, thereby playing an indispensable role in initiating infection. In this process, heptad repeats 1 and 2 (HR1 and HR2) of the S protein assemble into a complex called the fusion core, which represents a key membrane fusion architecture. To date, however, the MERS-CoV fusion core remains uncharacterized. In this study, we performed a series of biochemical and biophysical analyses characterizing the HR1/HR2 complexes of this novel virus. The HR sequences were variably truncated and then connected with a flexible amino acid linker. In each case, the recombinant protein automatically assembled into a trimer in solution, displaying a typical α-helical structure. One of these trimers was successfully crystallized, and its structure was solved at a resolution of 1.9 Å. A canonical 6-helix bundle, like those reported for other coronaviruses, was revealed, with three HR1 helices forming the central coiled-coil core and three HR2 chains surrounding the core in the HR1 side grooves. This demonstrates that MERS-CoV utilizes a mechanism similar to those of other class I enveloped viruses for membrane fusion. With this notion, we further identified an HR2-based peptide that could potently inhibit MERS-CoV fusion and entry by using a pseudotyped-virus system. These results lay the groundwork for future inhibitory peptidic drug design.

Middle East Respiratory Syndrome Coronavirus (Mers-Cov) Entry Inhibitors Targeting Spike Protein

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

MERS-CoV spike protein: a key target for antivirals

[Development of Peptidic MERS-CoV Entry Inhibitors].

Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Structure-based Discovery of Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor

MERS-CoV spike protein: Targets for vaccines and therapeutics

Antibodies And Vaccines Against Middle East Respiratory Syndrome Coronavirus

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Complex Structure of Mers-Cov Spike Glycoprotein with Human Receptor Dpp4

[Small Molecular Agents Against MERS-CoV Infection].

Development of Small-Molecule MERS-CoV Inhibitors.

Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies

From SARS to MERS: Evidence and Speculation

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Prospects for a MERS-CoV Spike Vaccine

Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein.

Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus.

Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors.

Designed miniproteins potently inhibit and protect against MERS-CoV